Vis børsmeldingen
· Gives Nordic Nanovector access to highly promising new technology that
enables the development and production of radionuclides for radioimmunoconjugate
-based approaches to cancer treatment, a rapidly growing global market
· The combined company is expected to have funding through 2025.
· Following the acquisition, the new Board of the combined company will
evaluate strategic alternatives for Nordic Nanovector’s existing pipeline of
patents in a standalone financing structure
· Agreement subject to approval at the annual general meeting of Nordic
Nanovector to be held on 28 June 2023 (“AGM”)
· The companies will host a joint presentation on 7 June at 10:00 a.m. CEST to
present the proposed acquisition
Nordic Nanovector ASA (OSE: NANOV) (“Nordic Nanovector” or the “Company”) and
Thor Medical AS (“Thor Medical”), a privately held company focused on the
production of alpha-emitting radionuclides for cancer treatment, today announce
that they have entered into a definitive share exchange agreement (the
“Agreement”) to combine the two companies in an all-share transaction (the
“Transaction”).
The agreed exchange ratio in the Transaction is on a 50-50 basis. Following
completion of the Transaction, Nordic Nanovector will own at least 98% of the
outstanding shares in Thor Medical. Assuming that Nordic Nanovector acquires all
of the shares in Thor Medical in the Transaction, then the former shareholders
of Thor Medical will own 50% of the post-transaction combined entity and
existing Nordic Nanovector shareholders will own 50%. Scatec Innovation AS,
currently the largest shareholder in Thor Medical, will become the largest
shareholder in the combined company after the Transaction with approximately
24.5% of the issued shares.
Ludvik Sandnes, Nordic Nanovector’s Interim CEO & CFO, commented: “Given the
complementary focus and expertise in our two companies, the Nordic Nanovector
Board and I believe the proposed acquisition of Thor Medical represents a
compelling option for Nordic Nanovector and its shareholders. There is
increasing interest in the development of radionuclide-based anti-cancer
therapies, and the combined company will have a significant opportunity to
address this growing market.”
Jon Magne Asmyr, Nordic Nanovector’s Chairman, added: “The acquisition of Thor
Medical is an important strategic step for Nordic Nanovector. Existing Nordic
Nanovector shareholders will post-transaction have significant ownership in a
very promising technology within the same field of industry and shorter time to
profitability. The plan following completion of the acquisition of Thor Medical
is to seek to out licence the patents from Nordic Nanovector’s pipeline and
finance further development of selected projects through a private company.”
About Thor Medical
Thor Medical, based in Oslo, Norway, is a private company that has developed a
proprietary technology for the manufacturing of radionuclides, primarily alpha
-particle emitters from natural resources. The high energy deposition and the
short range of alpha particles make it possible to eradicate cancer cells while
minimising damage to nearby healthy cells. Thor Medical will supply alpha
emitters to radiopharmaceutical companies for the development of innovative,
tumour-targeted cancer therapies. Thor Medical’s novel production process
requires no irradiation in nuclear reactors, and provides reliable,
environmentally friendly supply of radionuclides.
Thor Medical is in the process of relocating its laboratory and pilot facilities
to the University of Oslo. The University of Oslo, in close cooperation with
other research institutions in the sector, is in the process of establishing a
centre for nuclear research, focusing amongst other things on the use of
radionuclides in diagnostics and treatment of cancer.
Thor Medical was founded by Scatec Innovation AS and other shareholders of Thor
Energy AS, a company dedicated to research and development on the use of
thorium, a weakly radioactive chemical element with the symbol “Th”.
Alf Bjørseth, CEO of Thor Medical AS, commented: “At Thor Medical, we believe
our technology could bring the promise of radionuclide-based therapies to many
more cancer patients. As such, the combination with Nordic Nanovector will
enhance our ability and the speed at which we can bring this technology to
market. At the time of this announcement, Thor Medical shareholders with a
combined holding of more than 90% have committed their support for this
transaction, and we anticipate an exciting future for our combined company.”
Roy Hartvig Larsen, founder of Nordic Nanovector, commented: “As the suggested
Chair of the Technical Advisory Board, I am delighted with this proposed
agreement between Nordic Nanovector and Thor Medical to create a company that
will be positioned at the heart of radiopharmaceutical development, a rapidly
growing global market. I am also excited by the possibility of out licencing
Nordic Nanovector’s pipeline and programmes into a new private company. This
would represent a more appropriate environment to continue efforts to develop
this promising pipeline given the significant funding requirements and longer
timelines.”
Business focus post-Transaction
The radiotherapeutics market is expected to grow significantly in the coming
years and reach close to USD 20bn by 2030. Radionuclide therapy based on alpha
emitters is a promising technology for cancer treatment. However, alpha emitters
are in short supply and the current production processes are dependent on
irradiation, which is expensive and complex. Thor Medical has developed a
reliable and environmentally friendly production technology for alpha emitters,
independent of nuclear reactors and proton accelerators.
More than 50 companies, spanning established pharmaceutical companies and start
-ups, are engaged in the development and application of cancer radiotherapy.
Thor Medical has established relationships with several of these companies and
is continuing to utilize its laboratory and pilot-scale facilities to further
refine its product quality in close cooperation with potential customers.
Subject to the outcome of customer qualification processes, Thor Medical is
currently targeting to make a final investment decision on an industrial scale
manufacturing facility in 2025. Capex for the first industrial facility is
estimated at NOK 350m with revenues at >NOK 400m and EBITDA-margins at >50%.
As part of the Transaction, the Parties have agreed to investigate the potential
spin-out of Nordic Nanovector’s pipeline of patented development stage
candidates as an alternative and separate financing structure to continue
efforts to develop these assets.
Merger ratio
The agreed exchange ratio in the Transaction is on a 50-50 basis. If the Company
acquires all the shares in Thor Medical in the Transaction, the Company shall
issue up to 116,959,626 shares to the existing shareholders of Thor Medical,
subject to certain resolutions to be made at the AGM.
Board and management
Ludvik Sandnes has been nominated to be Chairman of the Board of Directors of
the combined company. In addition, John Andersen, Jr. and Mimi Berdal has been
nominated as Board members. Alf Bjørseth will take on the role as CEO. Roy
Hartvig Larsen will be Chairman of the Technical Advisory Board also consisting
of Harald Dugstad, Head of Radionuclide Technology and Supply, Bayer AG, and
Brit Farstad, Department Head, Safety & License, Institute for Energy Technology
Nuclear Sector.
Conditions for completion of the Transaction
The Transaction is subject to customary terms and conditions, including inter
alia the following being satisfied or waived by the parties:
· The AGM of Nordic Nanovector approving the Transaction
· Shareholders representing at least 98% of the shares in Thor Medical have
signed or adhered to the Agreement
· Election of the nominated Board of Directors
· The combined company’s continued listing on Oslo Børs
A notice calling for the AGM to approve the necessary corporate resolutions is
expected to be issued on 7 of June.
The Agreement is expected to be closed in Q2’23, following which the Company
intends to change its name to Thor Medical ASA. Shareholders representing
approx. 29% of the shares in Nordic Nanovector, including North Energy ASA, Jon
Magne Asmyr, Sciencons AS (a company controlled by Roy Hartvig Larsen) and
Ekornhuset AS (a company controlled by Ludvik Sandnes), have irrevocably agreed
to vote in favour of the Transaction on the AGM. Shareholders in Thor Medical
collectively holding more than 90% of the shares in Thor Medical on a fully
diluted basis have committed to support the Transaction.
Lock-up
Shareholders representing 86.03% of the shares in Thor Medical, including Scatec
Innovation AS, Scatec Invest II AS, Scatec Invest IV AS, Roht Invest AS,
Bergfald Holding AS, Brennebu AS and Alf Bjørseth, CEO have agreed, subject to
certain conditions, to a lock-up undertaking of 12 months following closing of
the Transaction. Nordic Nanovector shareholders Jon Magne Asmyr, Roy Hartvig
Larsen and Ludvik Sandnes have agreed the same.
Advisers
Carnegie Investment Bank is acting as financial advisor to Nordic Nanovector
with Advokatfirmaet CLP as legal advisor. Selmer is acting as legal advisor to
Thor Medical.
Presentation
A presentation by Nordic Nanovector and Thor Medical will be held in-person and
webcast at 10:00 CEST on 7 of June followed by a Q&A session. To join the
webcast please sign up via www.nordicnanovector.com.
Venue: Advokatfirmaet CLP DA, Sommerrogata 13, 0255 Oslo
The associated slides will be available at www.nordicnanovector.com and
www.scatecinnovation.noshortly before the webcast.
Contacts
Nordic Nanovector IR enquiries
Ludvik Sandnes, Interim CEO & CFO
+47 907 43 017
Thor Medical
John Andersen, Jr., Chairman of the Board
+47 90 17 40 80
Important information:
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to Section 5-12 the Norwegian Securities Trading Act. The stock
exchange announcement was published by Ludvik Sandnes, Interim CEO & CFO of
Nordic Nanovector ASA, at the time and date stated above in this announcement.
This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities. The distribution of this
announcement and other information may be restricted by law in certain
jurisdictions. Copies of this announcement are not being made and may not be
distributed or sent into any jurisdiction in which such distribution would be
unlawful or would require registration or other measures. Persons into whose
possession this announcement or such other information should come are required
to inform themselves about and to observe any such restrictions.
Matters discussed in this announcement constitute forward-looking statements.
Forward-looking statements are statements that are not historical facts and may
be identified by words such as “believe”, “expect”, “anticipate”, “strategy”,
“intends”, “estimate”, “will”, “may”, “continue”, “should” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although Nordic Nanovector believes that these assumptions were reasonable when
made, these assumptions are inherently subject to significant known and unknown
risks, uncertainties, contingencies and other important factors which are
difficult or impossible to predict and are beyond its control.
The information, opinions and forward-looking statements contained in this
announcement speak only as at its date, and are subject to change without
notice. Nordic Nanovector undertakes no obligation to review, update, confirm,
or to release publicly any revisions to any forward-looking statements to
reflect events that occur or circumstances that arise in relation to the content
of this announcement.
This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities.
Kilde
